Accelerating Medicines Partnership® Program for Alzheimer’s Disease (AMP® AD 2.0)
The Accelerating Medicines Partnership® Program for Alzheimer's Disease (AMP® AD) program is a precompetitive partnership among government, industry, and nonprofit organizations to transform the current model for developing new diagnostics and treatments for Alzheimer's disease. The goal of the second iteration of this transformative partnership is to expand the open-science, precompetitive enterprise and enable a true precision medicine approach to target and biomarker discovery.
This will be achieved by leveraging the investment by the National Institute on Aging in a series of foundational grants in the following strategic directions:
- Expand the molecular profiling in brain, CSF, and blood samples from diverse cohorts
- Generate longitudinal immunologic profiling data to enable dynamic modeling of the disease trajectory
- Expand the existing single-cell/single nucleus molecular profiling efforts to build predictive models of the disease at single cell resolution
The foundational grants support the AMP AD Data Coordinating Center at Sage Bionetworks and seven multi-institutional and highly cross-disciplinary research teams.
AMP AD 2.0 Foundational Grants
AMP AD Data Coordination Center (U24AG061340)
Principal Investigator:
Lara M. Mangravite, Sage Bionetworks
A Systems Approach to Targeting Innate Immunity in Alzheimer’s Disease (U01AG046139)
Contact Principal Investigator:
Nilufer Ertekin-Taner, Mayo Clinic
Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer’s Disease (U01AG046170)
Contact Principal Investigator:
Bin Zhang, Icahn School of Medicine at Mount Sinai
Multi-omic Network-Directed Proteoform Discovery, Dissection and Functional Validation to Prioritize Novel Alzheimer’s Disease Therapeutic Targets (U01AG061356)
Contact Principal Investigator:
Philip L. De Jager, Columbia University Health Sciences
AMP AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers (U01AG061357)
Contact Principal Investigator:
Allan I. Levey, Emory University
Metabolomic Signatures for Disease Sub-Classification and Target Prioritization in AMP AD (U01AG061359)
Contact Principal Investigator:
Rima F. Kaddurah-Daouk, Duke University
Identification of the Genetic and Transcriptomic Networks of Cognitive and Neuropathological Resilience to Alzheimer’s Disease Associated Viruses (U01AG061835)
Principal Investigator:
Benjamin Readhead, Arizona State University
Understanding the Protective and Neuroinflammatory Role of Human Brain Immune Cells in Alzheimer's Disease (R01 AG065582)
Contact Principal Investigator:
Panagiotis Roussos, Icahn School of Medicine at Mount Sinai
Estimated Funding
| Total project funding ($M) | Total NIH funding ($M) | Total partner funding ($M) |
|---|---|---|
| $83.3 | $69.8 | $13.5 |
AMP AD 2.0 Partners
Government
- National Institute on Aging (NIA)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Food and Drug Administration (FDA)
Industry
Nonprofit and Other Private Organizations
- Foundation for the NIH (FNIH)
- Alzheimer’s Association
- Gates Ventures
AMP AD 2.0 Governance
The AMP program is a multi-sector partnership managed by the FNIH. NIH and industry partners share expertise and resources in an integrated governance structure that enables the best-informed contributions to science from all participants.
The AMP AD Steering Committee convenes monthly to discuss project plans and review ongoing progress and milestones. The AMP AD Steering Committee is managed by the FNIH, and it consists of representatives from NIA, NINDS, FDA, and private partner organizations. NIA program staff members provide scientific and administrative direction and oversee the cooperative grants that constitute the foundation for the AMP AD 2.0 program.
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.
View Other AMP AD Pages
Last updated: October 21, 2024